Immune response markers in sentinel nodes may predict melanoma progression

Research output: Contribution to journalArticlepeer-review


We recently reported that variable expression of immune-response genes distinguishes tumor positive sentinel nodes in melanoma patients with malignant progression from those with non-progressing disease. Our results depict sentinel nodes as sites in which immune functions are associated with metastatic disease and identify CD30 as a host immune-related cancer prognostic marker and potential therapeutic target.

Original languageEnglish
Article numbere28498
Issue number4
Publication statusPublished - 2014


  • CD30
  • Expression profiles
  • Lymph node
  • Melanoma
  • Sentinel node

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology


Dive into the research topics of 'Immune response markers in sentinel nodes may predict melanoma progression'. Together they form a unique fingerprint.

Cite this